Description
| Product Name | CAT.No | Details |
| Neonatal TSH | BXE0682A | 96T |
Product Description
The Biorex Diagnostics Neonatal TSH (Thyroid Stimulating Hormone) Test is a high-quality neonatal screening assay developed for the early detection of congenital hypothyroidism (CHT) in newborns. Congenital hypothyroidism is a preventable endocrine disorder caused by reduced or absent thyroid hormone production, which can lead to impaired growth, neurodevelopmental delays, and lifelong health complications. Early diagnosis during the newborn period is essential, as prompt intervention with hormone replacement therapy can support normal cognitive development and prevent irreversible neurological damage. This assay provides a simple, reliable, and highly sensitive method for accurately detecting elevated TSH levels, making it ideal for clinical laboratories, hospitals, and national newborn screening programmes.
Key Features
- Newborn-Focused Sampling: Compatible with heel-prick dried blood spots, providing minimally invasive testing suitable for infants.
- Quantitative Measurement: Precisely measures TSH concentrations, enabling accurate identification of infants at risk for congenital hypothyroidism.
- Rapid and Reliable Results: Delivers reproducible results quickly, supporting timely clinical decision-making and early therapeutic intervention.
- High Sensitivity and Specificity: Detects both overt and mild thyroid dysfunction, ensuring accurate and dependable screening outcomes.
- User-Friendly Workflow: Simple procedures and ready-to-use reagents support efficient high-throughput neonatal screening.
- Laboratory Integration: Compatible with standard platforms and LIMS for streamlined sample handling and data management.
- Cost-Effective Solution: Designed for large-scale screening programmes, offering accurate neonatal testing at an economical price point.
Benefits
The Biorex Neonatal TSH Test offers a trusted and clinically relevant solution for newborn thyroid screening. Its precise, reproducible, and user-friendly design enables laboratories and clinicians to identify thyroid dysfunction early, reducing the risk of developmental impairment associated with untreated congenital hypothyroidism. The assay’s robust methodology and scalable workflow make it suitable for both routine hospital testing and population-wide newborn screening initiatives.
With its combination of accuracy, reliability, and operational efficiency, the Biorex Neonatal TSH Test ensures that at-risk infants are identified promptly, laboratory performance remains consistent, and clinical teams can deliver optimal patient care. This makes the assay an indispensable tool for neonatal endocrine screening and early congenital hypothyroidism management.
Contact Us for more information.